Advertisement

Capsaicin for Osteoarthritis Pain

  • Laura L. Laslett
  • Graeme JonesEmail author
Chapter
Part of the Progress in Drug Research book series (PDR, volume 68)

Abstract

Capsaicin appears to be effective for osteoarthritis pain but it is uncertain whether the effect has a dose response, is consistent across joints, or changes over time. Methods: Randomized controlled trials of topical capsaicin use in OA were identified from PubMed, EMBASE, and ISI Web of Knowledge. Effect on pain scores, patient global evaluation of treatment effectiveness and application site burning were assessed by standardised mean differences (SMD), using RevMan. Results: Five double–blind randomized controlled trials and one case–crossover trial of topical capsaicin use were identified. Formulations ranged from 0.025 to 0.075 %, and trial durations from 4 to 12 weeks. Trials assessed OA of the knee (n = 3), hand (n = 1), and a mix of joints (n = 2). Capsaicin treatment efficacy (vs. placebo) for change in VAS pain score was moderate, at 0.44 (95 % CI 0.25–0.62) over 4 weeks of treatment. There was no heterogeneity between studies, indicating no between-study differences, including effect of OA site or treatment concentration. Two studies reported treatment beyond 4 weeks, with divergent results. One study reported an effect size of −9 mm after 12 weeks, and maximal between-group differences at 4 weeks. A second study reported that between-group differences increased over time, up to 20 weeks. Capsaicin was reported as being safe and well–tolerated, with no systemic toxicity. Mild application site burning affected 35–100 % of capsaicin–treated patients with a risk ratio of 4.22 (95 % CI 3.25–5.48, n = 5 trials); incidence peaked in week 1, with incidence rates declining over time. Conclusions: Topical capsaicin treatment four times daily is moderately effective in reducing pain intensity up to 20 weeks regardless of site of application and dose in patients with at least moderate pain and clinical or radiologically defined OA, and is well tolerated.

Keywords

Standardise Mean Difference Visual Analog Scale Pain Visual Analog Score Burning Sensation Capsaicin Treatment 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. Altman RD, Aven A, Holmburg CE, Pfeifer LM, Sack M, Young GT (1994) Capsaicin cream 0.025% as monotherapy for osteoarthritis: a double-blind study. Semin Arthritis Rheum 23(6 (Suppl 3)):S25–33Google Scholar
  2. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC, Kvien TK, Schnitzer TJ (2000) Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR study group. N Engl J Med 343(21):1520–1528. doi: 10.1056/nejm200011233432103 PubMedCrossRefGoogle Scholar
  3. Baron R (2000) Capsaicin and nociception: from basic mechanisms to novel drugs. Lancet 356(9232):785–787. doi: 10.1016/s0140-6736(00)02649-0 PubMedCrossRefGoogle Scholar
  4. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, Lines C, Riddell R, Morton D, Lanas A, Konstam MA, Baron JA (2005) Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352(11):1092–1102. doi: 10.1056/NEJMoa050493 PubMedCrossRefGoogle Scholar
  5. Caughey GE, Roughead EE, Pratt N, Killer G, Gilbert AL (2011) Stroke risk and NSAIDs: an Australian population-based study. Med J Aust 195(9):525–529PubMedCrossRefGoogle Scholar
  6. Cohen J (1988) Statistical power analysis for behavioral sciences, 2nd edn. Lawrence Erlbaum Associates Incorporated, New JerseyGoogle Scholar
  7. Caterina MJ, Schumacher MA, Tominaga M, Rosen TA, Levine JD, Julius D (1997) The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature 389(6653):816–824. doi: 10.1038/39807 PubMedCrossRefGoogle Scholar
  8. Dieppe PA, Lohmander LS (2005) Pathogenesis and management of pain in osteoarthritis. Lancet 365(9463):965–973. doi: 10.1016/s0140-6736(05)71086-2 PubMedCrossRefGoogle Scholar
  9. Deal CL (1994) The use of topical capsaicin in managing arthritis pain: a clinician’s perspective. Semin Arthritis Rheum 23(6 Suppl 3):48–52CrossRefGoogle Scholar
  10. Deal CL, Schnitzer TJ, Lipstein E, Seibold JR, Stevens RM, Levy MD, Albert D, Renold F (1991) Treatment of arthritis with topical capsaicin: a double-blind trial. Clin Ther 13(3):383–395PubMedGoogle Scholar
  11. Fraenkel L, Bogardus ST Jr, Concato J, Wittink DR (2004) Treatment options in knee osteoarthritis: the patient’s perspective. Arch Intern Med 164(12):1299–1304. doi: 10.1001/archinte.164.12.1299 PubMedCrossRefGoogle Scholar
  12. Fusco BM, Giacovazzo M (1997) Peppers and pain. The promise of capsaicin. Drugs 53(6):909–914PubMedCrossRefGoogle Scholar
  13. Fortier LA, Nixon AJ (1997) Distributional changes in substance P nociceptive fiber patterns in naturally osteoarthritic articulations. J Rheumatol 24(3):524–530PubMedGoogle Scholar
  14. Jancso G, Kiraly E, Jancso-Gabor A (1977) Pharmacologically induced selective degeneration of chemosensitive primary sensory neurones. Nature 270(5639):741–743PubMedCrossRefGoogle Scholar
  15. Kidd BL, Morris VH, Urban L (1996) Pathophysiology of joint pain. Ann Rheum Dis 55(5):276–283PubMedCentralPubMedCrossRefGoogle Scholar
  16. Kenins P (1982) Responses of single nerve fibres to capsaicin applied to the skin. Neurosci Lett 29(1):83–88PubMedCrossRefGoogle Scholar
  17. Kosuwon W, Sirichatiwapee W, Wisanuyotin T, Jeeravipoolvarn P, Laupattarakasem W (2010) Efficacy of symptomatic control of knee osteoarthritis with 0.0125% of capsaicin versus placebo. J Med Assoc Thai 93(10):1188–1195PubMedGoogle Scholar
  18. McCleane G (2000) The analgesic efficacy of topical capsaicin is enhanced by glyceryl trinitrate in painful osteoarthritis: a randomized, double blind, placebo controlled study. Eur J Pain 4(4):355–360. doi: 10.1053/eujp.2000.0200 PubMedCrossRefGoogle Scholar
  19. McCarthy GM, McCarty DJ (1992) Effect of topical capsaicin in the therapy of painful osteoarthritis of the hands. J Rheumatol 19(4):604–607PubMedGoogle Scholar
  20. Nolano M, Simone DA, Wendelschafer-Crabb G, Johnson T, Hazen E, Kennedy WR (1999) Topical capsaicin in humans: parallel loss of epidermal nerve fibers and pain sensation. Pain 81(1–2):135–145PubMedCrossRefGoogle Scholar
  21. Pernow B (1983) Substance P. Pharmacol Rev 35(2):85–141PubMedGoogle Scholar
  22. Schaible HG, Grubb BD (1993) Afferent and spinal mechanisms of joint pain. Pain 55(1):5–54PubMedCrossRefGoogle Scholar
  23. Schnitzer TJ, Pelletier JP, Haselwood DM, Ellison WT, Ervin JE, Gordon RD, Lisse JR, Archambault WT, Sampson AR, Fezatte HB, Phillips SB, Bernstein JE (2012) Civamide cream 0.075% in patients with osteoarthritis of the knee: a 12-week randomized controlled clinical trial with a longterm extension. J Rheumatol 39(3):610–620. doi: 10.3899/jrheum.110192 PubMedCrossRefGoogle Scholar
  24. Szallasi A, Blumberg PM (1999) Vanilloid (Capsaicin) receptors and mechanisms. Pharmacol Rev 51(2):159–212PubMedGoogle Scholar
  25. Szallasi A, Blumberg PM (2007) Complex regulation of TRPV1 by vanilloids. TRP ion channel function in sensory transduction and cellular signaling cascades. CRC Press, Boca RatonGoogle Scholar
  26. Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, Anderson WF, Zauber A, Hawk E, Bertagnolli M (2005) Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352(11):1071–1080. doi: 10.1056/NEJMoa050405 PubMedCrossRefGoogle Scholar
  27. Theriault E, Otsuka M, Jessell T (1979) Capsaicin-evoked release of substance P from primary sensory neurons. Brain Res 170(1):209–213PubMedCrossRefGoogle Scholar
  28. Valdes AM, De Wilde G, Doherty SA, Lories RJ, Vaughn FL, Laslett LL, Maciewicz RA, Soni A, Hart DJ, Zhang W, Muir KR, Dennison EM, Wheeler M, Leaverton P, Cooper C, Spector TD, Cicuttini FM, Chapman V, Jones G, Arden NK, Doherty M (2011) The Ile585Val TRPV1 variant is involved in risk of painful knee osteoarthritis. Ann Rheum Dis 70(9):1556–1561. doi: 10.1136/ard.2010.148122 PubMedCentralPubMedCrossRefGoogle Scholar
  29. Wood JN, Winter J, James IF, Rang HP, Yeats J, Bevan S (1988) Capsaicin-induced ion fluxes in dorsal root ganglion cells in culture. J Neurosci 8(9):3208–3220PubMedGoogle Scholar
  30. Wojtys EM, Beaman DN, Glover RA, Janda D (1990) Innervation of the human knee joint by substance-P fibers. Arthroscopy 6(4):254–263PubMedCrossRefGoogle Scholar
  31. Zhang W, Nuki G, Moskowitz RW, Abramson S, Altman RD, Arden NK, Bierma-Zeinstra S, Brandt KD, Croft P, Doherty M, Dougados M, Hochberg M, Hunter DJ, Kwoh K, Lohmander LS, Tugwell P (2010) OARSI recommendations for the management of hip and knee osteoarthritis: part III: changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthr Cartil 18(4):476–499. doi: 10.1016/j.joca.2010.01.013 PubMedCrossRefGoogle Scholar

Copyright information

© Springer Basel 2014

Authors and Affiliations

  1. 1.Musculoskeletal UnitMenzies Research Institute Private bag 23HobartAustralia

Personalised recommendations